FDG PET 用于儿童霍奇金淋巴瘤的分期和疗效评估。本研究旨在根据使用 Deauville 评分 (DS) 对第二周期化疗后早期反应进行的中期 PET CT 评估来评估霍奇金淋巴瘤儿科患者的预后。它还确定 DS-3 是否提供了充分或不充分的反应。我们进行了一项回顾性队列研究，纳入了 504 名患有经典霍奇金淋巴瘤的儿科患者，这些患者从 2019 年 3 月起在埃及儿童癌症医院接受了基于 Euro-Net 方案的化疗直到 2022 年 10 月为止。与 DS 4 反应不足的患者相比，DS 1/2 和 DS 3 反应充分的患者的 3 年无事件生存率 (EFS) 几乎相同，分别为 91.9% 和 91.5% /5，EFS 为 80.4%（P=0.001）。中期 PET 评估时 DS 3 的患者被视为 DS 1/2 阴性。 DS 3组未接受放疗的患者由于存在阳性B症状、ESR>30或晚期，其3年EFS要差得多。对于反应不足 (DS4/5) 和不良预后特征的患者，放射治疗并未改善 3 年 EFS。他们仍然需要更先进的治疗。DS 1/2 和 DS 3 的 3 年 EFS 大致相同，优于 DS 4/5 患者的 3 年 EFS。因此，我们可以将 DS 3 分类为 FDG PET CT 摄取呈阴性。版权所有 © 2024 Wolters Kluwer Health, Inc. 保留所有权利。

FDG PET is required for the staging and response evaluation of pediatric Hodgkin lymphoma. This study aimed to evaluate the outcomes of pediatric patients with Hodgkin's lymphoma based on interim PET CT assessments of early response following second-cycle chemotherapy using the Deauville score (DS). It also determines whether DS-3 is providing an adequate or inadequate response.We conducted a retrospective cohort study including 504 pediatric patients with classic Hodgkin lymphoma who were treated with chemotherapy based on the Euro-Net protocol at the Children Cancer Hospital Egypt from March 2019 till the end of October 2022.Patients with adequate response DS 1/2 and DS 3 showed nearly the same 3-year event-free survival (EFS) of 91.9% and 91.5%, respectively, compared with those patients with inadequate response DS 4/5, who showed an EFS of 80.4% (P=0.001). Patients with a DS 3 at interim PET evaluation were considered negative as DS 1/2. Patients of DS 3 group who did not receive radiotherapy had a much worse 3-year EFS by the existence of positive B symptoms, an ESR>30, or an advanced stage. Radiation therapy did not improve the 3-year EFS in patients with an inadequate response (DS4/5) and poor prognostic characteristics. They still need more advanced treatment.DS 1/2 and DS 3 had about the same 3-year EFS, which is better than the 3-year EFS of patients with DS 4/5. Therefore, we can classify DS 3 as having negative FDG PET CT uptake.Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.